Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

45.79USD
28 Jul 2014
Price Change (% chg)

$-0.12 (-0.26%)
Prev Close
$45.91
Open
$45.84
Day's High
$45.92
Day's Low
$45.79
Volume
23,970
Avg. Vol
124,022
52-wk High
$48.42
52-wk Low
$32.21

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.98
Market Cap (Mil.): $96,850.96
Shares Outstanding (Mil.): 2,112.56
Dividend: 0.83
Yield (%): 1.81

Financials

  NVO.N Industry Sector
P/E (TTM): 26.58 35.64 36.09
EPS (TTM): 1.73 -- --
ROI: 69.67 18.92 18.19
ROE: 76.16 19.68 19.06
Search Stocks

Novo wins EU recommendation for two-in-one diabetes drug

LONDON - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.

25 Jul 2014

UPDATE 1-Novo wins EU recommendation for two-in-one diabetes drug

* Xultophy combines long-acting insulin deguldec and Victoza

25 Jul 2014

Novo sees two-in-one diabetes drug in Europe in first half of 2015

COPENHAGEN - Novo Nordisk, the world's largest insulin maker, said on Friday it expected European Commission marketing authorization for its new two-in-one insulin drug within three months after an EU medicines agency recommended the drug.

25 Jul 2014

Novo sees two-in-one diabetes drug in Europe in H1 2015

COPENHAGEN, July 25 - Novo Nordisk, the world's largest insulin maker, said on Friday it expected European Commission marketing authorisation for its new two-in-one insulin drug within three months after an EU medicines agency recommended the drug.

25 Jul 2014

Novo wins EU recommendation for two-in-one diabetes drug

LONDON, July 25 - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.

25 Jul 2014

BRIEF-EU medicines agency backs new drugs from Novo Nordisk, J&J, Gilead

July 25 - The European Medicines Agency: * EU medicines agency says recommends Novo Nordisk diabetes

25 Jul 2014

Denmark's Novo A/S enters hearing technology sector with Sonion purchase

COPENHAGEN, July 15 - Danish investment company Novo A/S said it bought hearing technology firm Sonion from Swedish private equity firm Altor, entering a market in which Denmark has been a major player for decades.

15 Jul 2014

Novo Nordisk to double revenue within a decade: deputy CEO

COPENHAGEN - Danish drugmaker Novo Nordisk, the world's biggest insulin maker, expects to more than double its annual revenue within a decade, its deputy chief executive Kaare Schultz told Reuters.

25 Jun 2014

Novo Nordisk diabetes drug appears effective for weight loss: study

- Novo Nordisk's big-selling diabetes drug Victoza appears to be an effective weight loss therapy, data from a late-stage clinical trial presented on Saturday demonstrated.

14 Jun 2014

Novo Nordisk diabetes drug appears effective for weight loss -study

June 14 - Novo Nordisk's big-selling diabetes drug Victoza appears to be an effective weight loss therapy, data from a late-stage clinical trial presented on Saturday demonstrated.

14 Jun 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €75.99 +0.01
Eli Lilly and Co (LLY.N) $63.04 -0.74

Earnings vs. Estimates

Search Stocks